Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 17:16:100280.
doi: 10.1016/j.lrr.2021.100280. eCollection 2021.

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

Ayşe Hilal Eroğlu Küçükdiler  1 , İrfan Yavaşoğlu  1 , Cem Selim  1 , Cansu Atmaca Mutlu  2 , Abdullah Karakuş  3 , Mahmut Bakır Koyuncu  4 , Oktay Bilgir  2 , Orhan Ayyıldız  3 , Eyüp Naci Tiftik  4 , Ali Zahit Bolaman  1
Affiliations

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

Ayşe Hilal Eroğlu Küçükdiler et al. Leuk Res Rep. .

Abstract

We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with intermediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.

Keywords: Acute myeloid leukemia; Gemtuzumab ozogamicin; Salvage treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Kaplan-Meier Survival Analysis.
See this image and copyright information in PMC

References

    1. Wu H., Wang M., Dai B., Zhang Y., Yang Y., Li Q., et al. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Deliv. 2017;24(1):1216–1229. doi: 10.1080/10717544.2017.1367976. - DOI - PMC - PubMed
    1. Yilmaz M., Wang F., Loghavi S., Bueso-Ramos C., Gumbs C., Little L., et al. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019;9(2):7. doi: 10.1038/s41408-019-0170-3. - DOI - PMC - PubMed
    1. Short N.J., Ravandi F. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. Expert Rev. Hematol. 2016;9:529–534. doi: 10.1080/17474086.2016.1187063. - DOI - PubMed
    1. Rashidi A., Weisdorf D.J., Bejanyan N. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br. J. Haematol. 2018;181:27–37. doi: 10.1111/bjh.15077. - DOI - PubMed
    1. DiNardo C.D., Stein E.M., Botton S., Roboz G.J., Altman J.K., Mims A.S., et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 2018;378:2386–2398. doi: 10.1056/NEJMoa1716984. - DOI - PubMed

LinkOut - more resources